LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil...

Open Forum Infectious Diseases 2018 / 11 Vol. 5; Iss. suppl_1

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J, H
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
5
Language:
english
Journal:
Open Forum Infectious Diseases
DOI:
10.1093/ofid/ofy229.2176
Date:
November, 2018
File:
PDF, 581 KB
english, 2018
Conversion to is in progress
Conversion to is failed